Tissue‑Specific mTORC1 Modulation Decouples Epigenetic Rejuvenation from Reprogramming‑Driven Oncogenesis

Hypothesis

Intermittent, tissue‑targeted mTORC1 inhibition administered during cyclic OSK expression uncouples epigenetic age reversal from the proliferative surge that underlies tumorigenesis. By dampening mTORC1‑driven HIF‑1α‑mediated glycolysis while preserving AMPK‑activated TET enzyme activity, the intervention favors a catabolic, epigenetically plastic state that supports demethylation without supplying the anabolic biomass needed for malignant expansion.

Mechanistic Rationale

1. mTORC1 as a glycolytic gatekeeper – Active mTORC1 sustains HIF‑1α translation, boosting glycolysis and nucleotide synthesis, which fuels the rapid cell‑cycle entry observed after OSK induction (3, 4). Inhibiting mTORC1 with rapamycin or rapalogs reduces HIF‑1α, lowering the biosynthetic flux that malignant cells require.
2. AMPK‑TET axis remains intact – mTORC1 inhibition activates AMPK, which can phosphorylate and enhance TET2/3 activity, promoting 5‑hmC generation and DNA demethylation independent of mTORC1 signaling (novel inference). This preserves the epigenetic resetting capacity of OSK factors.
3. Tissue‑specific delivery – Using nanoparticle carriers conjugated to tissue‑homing peptides (e.g., liver‑targeted GalNAc, muscle‑targeted M12) allows localized mTORC1 suppression where reprogramming is applied, sparing proliferative compartments such as intestinal crypts or hematopoietic stem cells where mTORC1 activity is essential for tissue homeostasis (5).

Testable Predictions

• Prediction 1: In mice receiving cyclic OSK expression plus liver‑targeted rapamycin nanoparticles, DunedinPACE‑equivalent murine clock will show a significant reduction (≥‑0.15 units) comparable to OSK alone, while liver‑specific tumor incidence after 12 months will not increase beyond baseline.
• Prediction 2: Metabolomic profiling will reveal decreased glycolytic intermediates (lactate, ATP citrate lyase product) and increased TET‑dependent hydroxymethylation (5‑hmC) in treated liver, whereas control OSK‑only livers show elevated glycolysis and Ki‑67 proliferation.
• Prediction 3: Rapamycin‑treated OSK mice will exhibit unchanged or improved functional readouts (e.g., serum ALT, grip strength) relative to OSK‑only, indicating that the survival‑mode shift does not compromise tissue‑specific rejuvenation benefits.

Falsifiability

If liver‑targeted mTORC1 inhibition abolishes the DunedinPACE improvement or fails to reduce tumorigenic markers despite OSK expression, the hypothesis is refuted. Conversely, if tumor incidence rises despite metabolic suppression, the assumed glycolytic dependency of reprogramming‑driven oncogenesis would be incorrect.

Experimental Outline

• Groups (n=10 per group): (1) OSK only, (2) OSK + liver‑targeted rapamycin, (3) OSK + non‑targeted rapamycin, (4) vehicle control.
• Intervention: Doxycycline‑inducible OSK (2 days on/5 days off) for 8 weeks; rapamycin nanoparticles administered 2 h before each OSK pulse.
• Readouts: murine epigenetic clock (blood & liver), 5‑hmC immunostaining, glycolytic flux (Seahorse), Ki‑67, γH2AX, serum chemistry, histopathology at 6 and 12 months.

By linking metabolic state to epigenetic plasticity, this framework translates the "civilization‑versus‑survival dial" into a precise, clinically actionable knob that can keep rejuvenation civil while holding tumorigenesis in check.